Full Text View
Tabular View
No Study Results Posted
Related Studies
Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients
This study is currently recruiting participants.
Verified December 2011 by Taipei Veterans General Hospital,Taiwan
Study NCT01491295   Information provided by Taipei Veterans General Hospital,Taiwan

First Received on October 27, 2011.   Last Updated on November 2, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chronic Hepatitis B
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis B, Chronic
Hepatitis, Chronic
More general conditions related to this trial
Digestive System Diseases
DNA Virus Infections
Enterovirus Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
Tenofovir disoproxil fumarate
Lamivudine plus adefovir
Additional drug interventions recognized in this trial
Adefovir
Adefovir dipivoxil
Lamivudine
Tenofovir
Tenofovir disoproxil
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Taipei Veterans General Hospital,Taiwan


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services